Oral benzquinamide in the treatment of nausea and vomiting.
The clinical antiemetic effect of bezquinamide by oral route at a dosage of 100 mg 3 times daily was evaluated by a controlled double-blind method in 183 studies of patients treated with 5-fluorouracil. The incidence of nausea and vomiting in benzquinamide-treated patients was equal to that in placebo-treated patients and significantly higher than that in patients treated with prochlorperazine, 10 mg 3 times daily. Sedation was the only significant side effect observed, and this occurred at essentially equal rates in benzquinamide- and prochlorperazine-treated patients.
D002986:Clinical Trials as Topic; D005472:Fluorouracil / Q000009:adverse effects; D006801:Humans; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D011346:Prochlorperazine / Q000009:adverse effects / Q000627:therapeutic use; D011807:Quinolizines / Q000009:adverse effects / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
D011807:Quinolizines; D005472:Fluorouracil; D011346:Prochlorperazine